NPPA Fixes Retail Prices for 39 New Drug Formulations under DPCO 2013

Key facts

• The National Pharmaceutical Pricing Authority (NPPA) fixed the retail prices of 39 new drug formulations under the Drugs (Prices Control) Order (DPCO), 2013.
• The notification was issued by the Department of Pharmaceuticals on July 8, 2026, under paragraphs 5, 11, and 15 of the DPCO, 2013.
• The price regulation covers medicines for cardiovascular diseases, diabetes, infections, cancer, glaucoma, HIV, and pain management.
• The retail price for Tenecteplase (TNK-tPA) Injection 50 mg was fixed at ₹60,238.27 per vial.
• Cardiovascular combinations include Amlodipine-Telmisartan-Metoprolol Succinate, Telmisartan-Chlorthalidone, Telmisartan-Cilnidipine, Bisoprolol-Telmisartan, Nebivolol-Amlodipine, and Amlodipine-Bisoprolol-Telmisartan.
• Anti-diabetic medicines include combinations of Dapagliflozin, Empagliflozin, Sitagliptin, Metformin, Glimepiride, and Voglibose.
• The notification covers anti-infective formulations like Amoxicillin-Clavulanate and ophthalmic solutions such as Netarsudil-Latanoprost and Nepafenac-Moxifloxacin.
• Other notified products include Imatinib Oral Solution, Vitamin D3 Oral Solution, and a HIV therapy kit containing Darunavir, Ritonavir, and Dolutegravir.
• Manufacturers must ensure retail prices do not exceed the notified rates, which are exclusive of Goods and Services Tax (GST).
• Existing manufacturers launching the same new drug within 12 months must file Form-IA on the Integrated Pharmaceutical Database Management System (IPDMS) 2.0.
• Manufacturers are required to issue revised price lists in Form-V and submit them to the NPPA and State Drug Controllers.
• Violations of the notified prices attract recovery of overcharged amounts with interest under the DPCO, 2013, and the Essential Commodities Act, 1955.